Skip to main navigation Overview Stock Information News & Events Financial Information Governance Resources Investor Relations Corporate Profile Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS® System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. News Releases NOV 10, 2021 NeuroPace Reports Third Quarter 2021 Financial Results NOV 10, 2021 NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy OCT 20, 2021 NeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021 View More Events NOV 10, 2021 AT 1:30 PM PST NeuroPace Third Quarter 2021 Earnings Call SEP 15, 2021 AT 11:35 AM PDT 2021 Baird Global Healthcare Conference SEP 14, 2021 AT 12:30 PM PDT 19th Annual Morgan Stanley Global Healthcare Conference View More Stock Quote Price Change Volume Yr High Yr Low Data Provided by Refinitiv. Minimum 15 minutes delayed. Shareholder Tools Copyright © 2021 Neuropace Footer Legal Legal Privacy Policy